Compassionate Use or Expanded Access of Dupilumab
August 27, 2026 updated by: Regeneron Pharmaceuticals
Unapproved Dupilumab Indications for Potential Compassionate Use or Expanded Access
Provide Compassionate Use or Expanded Access of Dupilumab
Study Overview
Detailed Description
Compassionate Use or Expanded Access requests are only being considered in response to Individual Patient or Treatment Investigational New Drug (IND) applications.
Availability will depend on location.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
- Treatment IND/Protocol
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Eligibility will be determined during the application review process.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
February 25, 2021
First Submitted That Met QC Criteria
February 25, 2021
First Posted (Actual)
March 2, 2021
Study Record Updates
Last Update Posted (Actual)
September 1, 2026
Last Update Submitted That Met QC Criteria
August 27, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Keywords
- Allergies
- Pemphigus Foliaceus
- Middle ear disease
- Eosinophilic Gastrointestinal Disease (EGID)
- Chronic Spontaneous Urticaria (CSU)
- Hand and Foot Dermatits
- Eosinophilic Esophagitis (EoE) - Pediatrics
- Hailey-Hailey Disease
- Nasal Polysposis (NP)
- Idiopathic Urticaria
- Dermal Hypersensitivity Reaction
- Actinic Prurigo
- Eosinophilic Cystitis
- Allergic Rhinitis with Nasal Polyposis
- Epidermolysis Bullousa Simplex (EBS)
- Cicatricial Pemphigoid
- Disseminated Coccidiomycosis
- Topical steroid withdrawal syndrome
- Eosinophilic Enterocolitis
Additional Relevant MeSH Terms
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Genetic Diseases, Inborn
- Autoimmune Diseases
- Immune System Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Eye Diseases
- Hypersensitivity, Immediate
- Eosinophilia
- Leukocyte Disorders
- Hematologic Diseases
- Esophageal Diseases
- Skin Diseases
- Gastroenteritis
- Urticaria
- Skin Diseases, Vascular
- Skin Diseases, Genetic
- Conjunctival Diseases
- Skin Diseases, Vesiculobullous
- Esophagitis
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Hemic and Lymphatic Diseases
- Chronic Urticaria
- Hypersensitivity
- Pemphigus
- Eosinophilic Esophagitis
- Pemphigus, Benign Familial
- Pemphigoid, Benign Mucous Membrane
- Actinic Prurigo
- dupilumab
Other Study ID Numbers
- R668-Dupilumab
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.